Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza
Key facts
- Who runs it
- Jiaxing AnDiCon Biotech Co.,Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 190 people enrolled
- Started
- 19 Aug 2024
- Ended
- 15 Apr 2025
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ADC189 tablets
- Baloxavir Marboxil tablets
- Placebo of ADC189 tablets
- Placebo of Baloxavir Marboxil tablets
- ADC189 granules
- Placebo of ADC189 granules
- Placebo of Oseltamivir granules
- Oseltamivir granules
- Record updated
- 23 September 2025
Who can take part
- Age
- 2 years to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 1. Patients aged 2 to 11 years at screening, both sex
- 2. Patients were diagnosed with Influenza A Vairus Infection/Influenza B Virus Infection
- 3. Parents willing and able to comply with study requirements, under the judgment of investigators
- 4. Onset of symptoms no more than 48 hours before presentation for screening
Who cannot take part
- 3. Patients with acute respiratory infection, tympanitis, sinusitis, or acute asthma attack within 2 weeks before screening
- 5. Other antiviral therapy is required during screening
- 4. Presence of a chronic disease or illness that may indicate increased risk for influenza-related complications
- 1. Patients with severe influenza
- 2. Pregnant or breast-feeding females
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China. This study will test a medicine for influenza in children younger than 5 year of age to see if it is safe and effective.
Read full original descriptionShow less
This is a multicenter, randomized, double-blind, controlled Phase III clinical study.
The study evaluates the pharmacokinetics, safety and efficacy of ADC189 tablets/granules following a single oral dose in children aged 2 to 11 years with influenza.
The 6 groups in the trial
- ADC189 tablets Group (Part 1)Treatment being tested
Around 30 patients, 6-11 years old.
Treatment: ADC189 tablets and Placebo of Baloxavir Marboxil tablets
- Baloxavir marboxil tablets Group (Part 1)Existing treatment, for comparison
Around 15 patients, 6-11 years old.
Treatment: Baloxavir Marboxil tablets and Placebo of ADC189 tablets
- ADC189 granules Group (Part 2A)Treatment being tested
Around 60 patients, 5-11 years old.
Treatment: Placebo of Baloxavir Marboxil tablets and ADC189 granules
- Baloxavir marboxil tablets (Part 2A)Existing treatment, for comparison
Around 30 patients, 5-11 years old.
Treatment: Baloxavir Marboxil tablets and Placebo of ADC189 granules
- ADC189 granules (Part 2B)Treatment being tested
Around 20 patients, 2-4 years old.
Treatment: ADC189 granules and Placebo of Oseltamivir granules
- Oseltamivir granules (Part 2B)Existing treatment, for comparison
Around 10 patients, 2-4 years old.
Treatment: Placebo of ADC189 granules and Oseltamivir granules
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate Pharmacokinetics, Safety and Efficacy of ADC189 Tablets/Granules in Children 2-11 Years Old With Influenza
- Record updated
- 23 September 2025